ArticleFrontiers in oncology2025
Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hairy cell leukemia variant (HCL-v) is a rare and more aggressive subtype of B-cell leukemia. While it shares certain clinical features with classical hairy cell leukemia (HCL-c), HCL-v typically follows a more malignant course and responds poorly to conventional therapies. We report a case of HCL-v in a 57-year-old male who was admitted with splenomegaly and abnormal blood counts. Based on bone marrow morphology and immunophenotyping, a diagnosis of HCL-v was established. The patient was treated with a combination of obinutuzumab and bendamustine. Following treatment, his blood counts normalized, spleen size significantly reduced, and bone marrow reassessment confirmed complete remission (CR) with minimal residual disease (MRD) negativity. The patient is currently undergoing maintenance therapy with obinutuzumab and remains in good clinical condition. This case demonstrates the promising clinical efficacy of obinutuzumab combined with bendamustine in treating HCL-v, suggesting its potential as a therapeutic option. However, long-term outcomes warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.